Evidence map›Paper›PMID 34852010›Full record

ArticlePloS one2021

Hematological malignancies in the Northwest Ethiopia.

Bamlaku Enawgaw, Melak Aynalem, Mulugeta Melku, Fikir Asrie, Molla Abebe, Aregawi Yalew, Tiruzer Bekele, Nebiyu Mesfin, Mulugeta Ayalew, Elias Shiferaw

Abstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Bamlaku EnawgawUniversity of Gondar, College of Medicine and Health Science, School of Biomedical and Laboratory Sciences, Department of Hematology and Immunohematology, Gondar, Ethiopia.
Melak AynalemUniversity of Gondar, College of Medicine and Health Science, School of Biomedical and Laboratory Sciences, Department of Hematology and Immunohematology, Gondar, Ethiopia.ORCID 0000-0003-1461-0160
Mulugeta MelkuUniversity of Gondar, College of Medicine and Health Science, School of Biomedical and Laboratory Sciences, Department of Hematology and Immunohematology, Gondar, Ethiopia.
Fikir AsrieUniversity of Gondar, College of Medicine and Health Science, School of Biomedical and Laboratory Sciences, Department of Hematology and Immunohematology, Gondar, Ethiopia.
Molla AbebeUniversity of Gondar, College of Medicine and Health Science, School of Biomedical and Laboratory Sciences, Department of Hematology and Immunohematology, Gondar, Ethiopia.
Aregawi YalewUniversity of Gondar, College of Medicine and Health Science, School of Biomedical and Laboratory Sciences, Department of Hematology and Immunohematology, Gondar, Ethiopia.
Tiruzer BekeleUniversity of Gondar, College of Medicine and Health Science, School of Medicine, Department of Pathology, Gondar, Ethiopia.
Nebiyu MesfinUniversity of Gondar, College of Medicine and Health Science, School of Medicine, Department of Internal Medicine, Gondar, Ethiopia.
Mulugeta AyalewUniversity of Gondar, College of Medicine and Health Science, School of Medicine, Unit of Pediatric Hematology Oncology, Gondar, Ethiopia.
Elias ShiferawUniversity of Gondar, College of Medicine and Health Science, School of Biomedical and Laboratory Sciences, Department of Hematology and Immunohematology, Gondar, Ethiopia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe effect of malignant diseases is increasing globally, particularly in developing countries as shown by recent cancer statistics from the world health organization reports. It is anticipated that with an increase in life expectancy consequent upon the improved standard of living and increasing urbanization, the burden of hematological malignancies in sub-Saharan Africa particularly in Ethiopia is likely to increase recently. Therefore, this study was aimed to determine the incidence and trend of hematological malignancy in Northwest Ethiopia.

methodsA facility-based retrospective study was conducted from 2015 to 2019 at the University of Gondar and Bahir-Dar Felegehiwot comprehensive specialized hospitals. Hematological malignancy data were collected by using a data collection sheet that was consisted of patients' socio-demography, clinical, and laboratory data. Then, data were entered into Epi-info 3.5.1 and exported to SPSS version 20 for analysis. Skewness and kurtosis were used to check data distribution. Descriptive statistics were summarized as percentages, means, and standard deviations of background variables, and the trend were analyzed.

resultsIn this study, a total of 1,342 study participants were included. The mean age of study participants was 41.49 ± 16.3 years with a range of 1 to 92 years. About 58.3%, 52.2%, and 80% of the cases were observed among males, 18-45 age group, and urban residences, respectively. Of the total cases, 92.9% and 7.1% were lymphoma and leukemia, respectively. On the other hand, from lymphoma cases, 72.3% and 27.7% were HL and NHL, respectively while from leukemic cases, 61.1%, 23.2, 6.3%, 4.2%, and 5.3% were CLL, ALL, CML, AML, and other HM types, respectively. In this study, there was no trend.

conclusionWe concluded that lymphoma was the dominant type of hematological malignancy observed in northwest Ethiopia. The study indicated that the majority of cases were observed among male, urban residents, and adult populations aged 18-45 years. Therefore, special focus should be given to the highly affected population. Further, a prospective cohort study should be conducted for a better understanding of the prevalence and associated factors to it.

Indexed as

AdolescentAdultAgedAged, 80 and overAge FactorsChildChild, PreschoolCohort StudiesEthiopiaHematologic NeoplasmsHospitals, SpecialHumansIncidenceInfantMiddle AgedProspective Studies

Identifiers

PMID34852010
PMCPMC8635328

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.